93
Participants
Start Date
July 23, 2012
Primary Completion Date
October 30, 2014
Study Completion Date
October 30, 2014
Oral Budesonide Suspension (MB-9)
OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
Placebo
University of Pennsylvania, Philadelphia
Carilion Pediatric Gastroenterology, Roanoke
University of North Carolina at Chapel Hill, Chapel Hill
Children's Center for Digestive Health, Greenville
Children's Center for Digestive Healthcare, Atlanta
Vanderbilt University Medical Center, Nashville
Great Lakes Gastroenterology, Mentor
The Cincinnati Center for Eosinophilic Disorders, Cincinnati
Indiana University Health University Hospital, Indianapolis
Riley Hospital for Children, Indianapolis
University of Iowa Hospitals and Clinics, Iowa City
The Mayo Clinic, Rochester
Center for Children's Digestive Health, Park Ridge
Northwestern Scool of Medicine, Chicago
Children's Memorial Hospital, Chicago
The Children's Hospital, Aurora
University of Utah Healthcare, Salt Lake City
Phoenix Children's Hospital, Phoenix
UCSD Rady Children's Hospital, San Diego
Children's Hospital of Orange County, Orange
Tufts Medical Center, Boston
Children's Hospital Boston, Boston
Rhode Island Hospital, Providence
Lead Sponsor
Shire
INDUSTRY